Open label and single cohort study of edaravon on Muro disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex :Kii ALS/PDC)

Trial Profile

Open label and single cohort study of edaravon on Muro disease (amyotrophic lateral sclerosis and parkinsonism-dementia complex :Kii ALS/PDC)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2014

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis; Dementia; Parkinsonian disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top